NMD670 is a first-in-class small molecule inhibitor of skeletal muscle-specific chloride channel (ClC-1) with an EC50 of 1.6 μM. It improves muscle weakness and fatigue in neuromuscular diseases and may serve as a potential therapeutic approach for Myasthenia Gravis (MG).

NMD670 is a first-in-class small molecule inhibitor of skeletal muscle-specific chloride channel (ClC-1) with an EC50 of 1.6 μM. It improves muscle weakness and fatigue in neuromuscular diseases and may serve as a potential therapeutic approach for Myasthenia Gravis (MG).

NMD670 is a first-in-class small molecule inhibitor of skeletal muscle-specific chloride channel (ClC-1) with an EC50 of 1.6 μM. It improves muscle weakness and fatigue in neuromuscular diseases and may serve as a potential therapeutic approach for Myasthenia Gravis (MG).

Osimertinib dimesylate (Mereletinib dimesylate, AZD-9291 dimesylate) is a potent, mutant-selective, irreversible inhibitor of EGFR kinase activity with an IC50s of 12 and 1 nM against EGFRL858R and EGFRL858R/T790M, respectively. It demonstrates anti-tumor activity in xenograft and transgenic T790M EGFR mutant models, supporting its use in non-small cell lung cancer (NSCLC) research.

Osimertinib dimesylate (Mereletinib dimesylate, AZD-9291 dimesylate) is a potent, mutant-selective, irreversible inhibitor of EGFR kinase activity with an IC50s of 12 and 1 nM against EGFRL858R and EGFRL858R/T790M, respectively. It demonstrates anti-tumor activity in xenograft and transgenic T790M EGFR mutant models, supporting its use in non-small cell lung cancer (NSCLC) research.

Osimertinib dimesylate (Mereletinib dimesylate, AZD-9291 dimesylate) is a potent, mutant-selective, irreversible inhibitor of EGFR kinase activity with an IC50s of 12 and 1 nM against EGFRL858R and EGFRL858R/T790M, respectively. It demonstrates anti-tumor activity in xenograft and transgenic T790M EGFR mutant models, supporting its use in non-small cell lung cancer (NSCLC) research.

Osimertinib dimesylate (Mereletinib dimesylate, AZD-9291 dimesylate) is a potent, mutant-selective, irreversible inhibitor of EGFR kinase activity with an IC50s of 12 and 1 nM against EGFRL858R and EGFRL858R/T790M, respectively. It demonstrates anti-tumor activity in xenograft and transgenic T790M EGFR mutant models, supporting its use in non-small cell lung cancer (NSCLC) research.

INF 195 is an NLRP3 inhibitor which inhibits NLRP3-driven macrophage pyrodeath and IL-1β release. At low dose, INF 195 can reduce the infarct size of isolated mouse hearts and effectively prevent myocardial ischemia/reperfusion injury.

INF 195 is an NLRP3 inhibitor which inhibits NLRP3-driven macrophage pyrodeath and IL-1β release. At low dose, INF 195 can reduce the infarct size of isolated mouse hearts and effectively prevent myocardial ischemia/reperfusion injury.

INF 195 is an NLRP3 inhibitor which inhibits NLRP3-driven macrophage pyrodeath and IL-1β release. At low dose, INF 195 can reduce the infarct size of isolated mouse hearts and effectively prevent myocardial ischemia/reperfusion injury.